TOTAL BODY CLEARANCE AND MEAN RESIDENCE TIME OF TAMOXIFEN IN FEMALE HEALTHY SUBJECTS by Shahbaz, K
©SRDE Group, All Rights Reserved. Int. J. Res. Dev. Pharm. L. Sci. 2142
International Journal of Research and Development in Pharmacy and Life Sciences
Available online at http//www.ijrdpl.com
April - May, 2016, Vol. 5, No.3, pp 2142-2146
ISSN (P): 2393-932X,   ISSN (E):  2278-0238
Research Article
TOTAL BODY CLEARANCE AND MEAN RESIDENCE TIME OF TAMOXIFEN IN FEMALE
HEALTHY SUBJECTS
1. Institute of Pharmacy, Physiology and Pharmacology, University of Agriculture, Faisalabad, Pakistan.
2. Department of Oncology,  (Center for Breast Cancer) Perfect Health Pvt. Ltd, Islamabad.
*Corresponding author’s Email: dr.shahbaz86@gmail.com
(Received: February 08, 2016; Accepted: March 30, 2016)
ABSTRACT
Objective: To investigate total body clearance and mean residence time after single oral dose of tamoxifen in female healthy subjects focusing on two concepts
pharmenzymonetics and pharmgeonetics for the first time in Pakistan.
Methodology: Two parameters were investigated in eight healthy female subjects after single oral dose of 20mg tablet Nolvadex brand. Blood samples were
collected and plasma concentration was determined by Gradient HPLC method to evaluate the total body clearance and mean resident time. Subjects were kept
under observation for 4 weeks detecting any adverse signs or symptoms.
Results: Value of total body clearance mean ±SE was 39.7 ± 0.55 L/Hr/Kg and that of mean residence time MRT is 15.18 ± 0.19 Hours. There were no adverse
signs reported during 4 weeks of direct observation of subjects after oral single dose. Blood pressure, temperature, pulse rate and appearant activity of subjects
remained normal.
Conclusion: The total body clearance and MRT of tamoxifen is greater as compared to literature value in the healthy females of Pakistan due to pharmgeonetics.
Keywords: Total body clearance, mean residence time, tamoxifen body clearance, total body clearance breast cancer medicine.
INTRODUCTION
Breast cancer is the second highly important cause of
mortalities in the world. It does not cover only women but
also men and food animals. Metastatic breast cancer is more
drastic as the main causative agent is not known. Although,
multiple causes have been known to be involved in the
metastatic breast cancer, but still chemotherapy is a question
to absolutely treat this cancer (Shahbaz et al., 2014). 1.3
million Women suffer from breast cancer in United States.
Similarly 1 out of every 8 women had breast cancer
reported in 2014 (Breast Cancer, 2013). Not only humans
but also animals become victim of breast cancer as shown by
the research on cow’s breast cancer at Harvard University in
2006.
Total Body clearance and mean residual time are important
pharmacokinetics parameters. CLB tells speed of drug
eliminated, metabolized or distributed throughout the body
(Boomers, 2015). Thus how a drug reacts pharmacologically
is widely based on the total body clearance of a drug.
Mean residence time is how long tamoxifen molecule stays in
the body is a critical parameter for the better breast cancer
treatment. As the tamoxifen is highly protein bound its MRT
differs widely based on the metabolism of tamoxifen
prodrug. Due to geographical changes this metabolism
differs widely among the individuals of different countries.
Tamoxifen is an anti breast cancer drug being used in the
females of Pakistan for more than 5- 10years after being
diagnosed with breast cancer. Therefore total body
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clearance and mean residence time was calculated in
females. However no enzymatic test is carried out before
prescription as metabolism of this medicine depends on the
enzyme CYP2D6 variants (Abraham et al., 2010, Kristine et
al., 2012). Thus how long tamoxifen will stay in the body is
an essential factor not been studied in Pakistan for this drug.
Optimal therapeutic usage of imported drug is not achieved
due to change of total body clearance and mean residence
time.
MATERIAL AND METHODS
CLb and MRT were investigated in the eight healthy female
subjects selected from University or nearby residential area
of Faisalabad.
Selection Criteria
Volunteers of age group 35-60 years were selected after
physical examination and clinical history to be declared as
healthy. All volunteers were informed about the objective of
study, frequency of sampling and possible side effects of
drug and written consent with each volunteer was made.
Drug/ Chemicals
Tamoxifen, 20 mg tablet from ICI Pvt. Ltd., Lahore, Pakistan
was taken.
The following chemicals used in the entire study were of
HPLC grade:
• Ammonium acetate(Merck, Germany)
• Acetonitrile (Fischer Scientific Limited, UK)
• Methanol (Fischer Scientific Limited, UK)
• Deionized water.
A single dose of Tamoxifen 20 mg tablet of Nolvadex brand
was given orally to each volunteer after breakfast. In all
experiments, a blood blank sample was collected before
drug administration. Blood sample of 5ml each was collected
from the cubital vein of each volunteer either directly with
the help of a disposable syringe or through I.V cannula of 20
gauge needle at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after
oral dose. The pH of fresh sample of blood was noted in
each experiment by a pH meter (Beckman HS, Germany)
with a glass electrode at 370C. Collected blood was
centrifuged and plasma was separated and stored at -20C.
Drug Analysis
After determination of Tamoxifen concentration in plasma
samples using HPLC (Sykam, S-3210) analytical method
using UV/Vis detector (Sykam, S-3210) (Kashtiaray et al.
2011), CLB and MRT calculations were done with the
computer programme MW/PHARM version 3.02 by F.
Rombout, in cooperation with University Centre for Pharmacy,
Department of Pharmacology and Therapeutics, University of
Gronigen & Medi/Ware, copy right 1987-1991.
RESULTS
The mean ± SE total body clearance (Clb) determined was
39.7 ± 0.55 L/hr/Kg. The mean ± SE mean residence time
(MRT) of tamoxifen after single oral dose was 15.18 ± 0.19
hours. The mean ± SE values of total body clearance (CLb)
and mean residence time (MRT) are given in the Table 1.
Similarly the figure 1 shows variation of the two parameters
among the eight individuals of same environment and health
condition. Fig. 1 depicts no significant difference of CL and
MRT among the individuals which confirms that the two
parameters do not alters under same geographical and
health conditions. Figure 2 shows the effect of total body
clearance on the mean residence time and hence the bars of
volunteer 5 show an inverse relation between the two i.e. as
the clearance showed a slight change the MRT also changed.
Similarly slight decrease in total body clearance suggests
slight increase in the mean residence time. This effect is also
clear for volunteer 5 in Fig. 1.
After single oral dose of chemotherapeutic medicine
tamoxifen, no notable adverse signs were observed and
reported within 4 weeks of intake of tablet.
This study also suggests that a single dose study do not
apparently affects the human subjects. However clinical tests
were not carried out in this study.
Table 1: Mean ± SE total body clearance and mean
residual time of Tamoxifen following oral administration of













Mean ±SE 39.7±0.554402 15.18±0.150
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DISCUSSION
The total body clearance of 39.7 ± 0.55 L/hr/kg is higher
than one of the study 11.34 L/Hr/Kg (Lien et al., 1990)
which is due to more water intake and health condition of
female volunteers and the later study was performed on
patients rather than healthy volunteers. As in breast cancer
patients more estrogen (negative feedback) leads to more
competition for tamoxifen molecule to retain in the body
(Martine et al.. 2013) and less total body clearance. In the
present study, the higher value of Clβ for Tamoxifen than
literature cited may be endorsed higher Vd. Half life of drug
is dependent on the Clβ ( Total body clearance of that
drug).The alteration in total body clearance affects the half
life ( Prescott and Baggot, 1988).
This is described by term “pharmenzymonetics” and
“pharmgeonetics”.
Table 2: Sign and symptoms measured following oral







Single Dose In 4
Weeks
1 Temperature Normal*
2 Pulse rate Normal *





8 Apparent activity Normal
Figure 1: Variation in Total body clearance and Mean Residual Time of Tamoxifen due to environment after single oral
administration of 20mg tablet in 8 healthy female volunteers.
Figure 2: Effect of Total body clearance on Mean Residual Time of Tamoxifen after single oral administration of 20mg tablet in 8
healthy females.
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Pharmgeonetics is the study of changed effect of medicine in
the living body due to change of environment and genetic
makeup. Similarly pharmenzymonetics is the study of
changed behavior of medicine in the living body due to
enzyme and genetic makeup. Several enzymes are involved
in these metabolic pathways of tamoxifen, with CYP2D6
playing a pivotal role (Golander et al., 1980). In subject no.
5, the decrease though very slight in CL showed similar slight
increase in the MRT which defines the accuracy of study and
natural phenomenon i.e. increase clearance is inversely
proportional to residence time.
The clearance of Tamoxifen in the present study is under the
range of 41.2-40.8 l/hr/kg.
Total body clearance is altered in body due to various
factors include:
1. Fraction of the unbound drug in the body.
2. Maximal ability of the organ to remove the drug.
3. Blood flow to the different organs
Mean residence time is the time required to eliminate the
63% of the drug from the body. Or mean residence time is
also defined as the estimate of the persistence time of the
drug in the body. The mean residence time of single dose of
Tamoxifen 20 mg after oral administration was under the
ranged from 15.0-14.2hr of with mean ± S.D was 15.1 ±
0.15hours in the present study. This suggests that health
sector is far away from the main therapeutic outcomes and
standard treatment guidelines as the research based on
geographical region is missing (Shahbaz et al., 2015). No
adverse signs after single dose opens way for more clinical
trials.
CONCLUSION
The changed values of CL and MRT than literature value
suggests that the healthy volunteers of Pakistan behaves in a
faster way for clearance of tamoxifen. A comparison of
different pharmacokinetics parameter of various drugs in
different species of animals verified considerable deviation
when compared with the literature values (Nawaz, 1982;
Javed et al., 2009).Not only species but we may observe this
change in various age groups. As the value obtained of two
parameters in current study are different as compared to
other species as mice, rat and even dogs. This change is due
to pharmaenzymonetics and pharmgeonetics.It may also be
concluded in case of Cyp2D6 which varies in different
individuals that everybody is a different case for treatment.
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